SkinBioTherapeutics plc
SkinBioTherapeutics files new patent application
Manchester, UK - 14 May 2018 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, announces a new patent filing.
The patent application is to cover the use of SkinBiotix® for increasing filaggrin levels in skin.
Filaggrin is a protein which is vital to the formation of the outermost protective layer of skin. If filaggrin is absent, skin tends to become dry and irritated. It has been shown that those with severe forms of eczema can have half the level of filaggrin as a healthy individual. Work performed at the Company's laboratories has demonstrated that SkinBiotix® can significantly increase the amount of filaggrin in human skin models.
This is the second successful test of the Company's technology, following earlier proof that SkinBiotix® increases the 'tight junction' which exists in the inner layer of skin. The observation that the technology can improve both the surface and inner layers of skin suggests that SkinBiotix® will be therapeutically useful in a range of conditions, such as eczema.
Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:
"SkinBiotix® is continuing to prove its uniqueness as a platform via scientific testing. Following the successful work in skin models on fillagrin production, we are looking to increase the value and scope of our intellectual property with the filing of this patent.
"This is a continuation of our strategy to create an IP portfolio that allows us to robustly protect what we believe is a technology of significant commercial value in key global dermatalogical markets."
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Dr. Cath O'Neill, CEO Doug Quinn, CFO |
Tel: +44 (0) 161 468 2760 |
Turner Pope Investments (Joint Broker) Ben Turner / James Pope Northland Capital Partners (Joint Broker) John Howes / Tom Price |
Tel: +44 (0) 20 3621 4120 Tel: +44 (0) 20 3861 6625 |
Instinctif Partners (Media Relations) Melanie Toyne-Sewell / Deborah Bell |
Tel: +44 (0) 20 7457 2020 [email protected] |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.
